Patrick Starlinger

2 weeks ago | hpbonline.org | Chris Varghese |Elizabeth Habermann |Patrick Starlinger

Get full text accessLog in, subscribe or purchase for full access. References1. Nitecki, S.S. ∙ Sarr, M.G. ∙ Colby, T.V. ... Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann. Surg. 1995; 221:59-662. Sperti, C. ∙ Pasquali, C. ∙ Piccoli, A. ... Survival after resection for ductal adenocarcinoma of the pancreasBr. J. Surg. 1996; 83:625-6313. Groot, V.P. ...

Dec 27, 2024 | onlinelibrary.wiley.com | Patricia Carey |Animesh Pardanani |Patrick Starlinger |Ayalew Tefferi

To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.